MeritValue

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZdata completeness 75%17 fiscal years on file

Data notes: no data for concept 'capex'

The thesis, from the filings

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. earns about -699% on invested capital, and has bought back 27% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$87,7541$88,6002$9,0003$11,0004$6,0004
Net income$19.2M5−$10.1M6−$5.29M7−$5.49M8−$6M8
Operating cash flow−$2.22M9−$7.8M10−$8.03M11−$5.3M12−$5.86M12
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$10.7M13$8.32M14$3.47M15$5.94M15$7.21M15
Diluted shares3.2M10.9M1.4M1.5M2.4M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$31.54
your share of equity
Profit it earned you last year
−$25.16
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $31.54 of net worth that earned you −$25.16 last year.

iii. Is this a good business?
Moat signal · return on invested capital
-699% avg · 5y
FY21 —FY22 -106%FY23 -61%FY24 -1082%FY25 -1545%

It earned an average -699% on invested capital over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−27% shares · 5y

Share count is down 27% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001477932-23-002123 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001477932-24-001431 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001477932-25-001736 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001477932-26-001517 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001477932-23-002123 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001477932-24-001431 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001477932-25-001736 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001477932-26-001517 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001477932-23-002123 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001477932-24-001431 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001477932-25-001736 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001477932-26-001517 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-12-31 · accession 0001477932-22-001741 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2022-12-31 · accession 0001477932-25-001736 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  15. 10-K · period ending 2023-12-31 · accession 0001477932-26-001517 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)